FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX) – Research analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of ABIVAX Société Anonyme in a note issued to investors on Tuesday, March 25th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($3.14) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

A number of other analysts have also recently issued reports on ABVX. JMP Securities reiterated a “market outperform” rating and set a $33.00 target price on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $38.00.

ABIVAX Société Anonyme Trading Down 3.8 %

Shares of ABIVAX Société Anonyme stock opened at $6.82 on Wednesday. The business’s fifty day moving average price is $6.79 and its 200 day moving average price is $8.41. ABIVAX Société Anonyme has a twelve month low of $5.50 and a twelve month high of $16.63.

Institutional Trading of ABIVAX Société Anonyme

A number of hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC purchased a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at $29,000. R Squared Ltd acquired a new position in ABIVAX Société Anonyme in the 4th quarter worth $36,000. Bank of America Corp DE boosted its position in ABIVAX Société Anonyme by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $85,000. Finally, Guggenheim Capital LLC purchased a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth about $92,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.